Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes

pharmafile | April 15, 2020 | News story | Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma 

Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with the authorisation of four key therapies for NHS patients in Scotland.

Janssen’s Stelara (ustekinumab) was among the approved products, authorised for moderately to severely active ulcerative colitis in patients for which conventional therapies or biologics are unsuitable. It’s estimated that around 23,500 people in Scotland live with some form of the condition. The SMC has previously approved Stelara in plaque psoriasis, psoriatic arthritis and Crohn’s disease

Biogen’s Fampyra (fampridine) also secured authorisation for the improvement of walking in adult multiple sclerosis (MS) patients with walking disability. The availability of the drug helps tackle an unmet need, as there are currently no approved treatments for MS patients who experience difficulty walking. 

Also approved was Sanofi’s Suliqua (insulin glargine/lixisenatide), authorised as an additional treatment option to control blood glucose levels, when combined with metformin, in type 2 diabetes patients who have not been able to bring their levels under control with metformin and insulin alone.

And finally, Sandoz’s Rimzoic (naldemedine) was approved to treat constipation brought on by the use of opioid painkillers, a very common and difficult to treat side-effect of such medications, providing an alternative option to laxatives.

Matt Fellows

Related Content

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended …

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

Latest content